MICHELLE SWAN: Open Payments
NPI 1801578646 · AMES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,311 in 73 payments from 17 companies in 2025. Trend: 2023 $527 · 2024 $1,053 · 2025 $1,311
Food & beverage: $1,311
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 15 | $354 |
| ABBVIE INC. | 13 | $187 |
| Lundbeck LLC | 8 | $140 |
| HARMONY BIOSCIENCES LLC | 5 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Tris Pharma Inc | 4 | $61 |
| Neurocrine BioSciences, Inc. | 3 | $58 |
| Gilead Sciences, Inc. | 3 | $56 |
| Collegium Pharmaceutical, Inc. | 3 | $50 |
| E.R. Squibb & Sons, L.L.C. | 3 | $46 |
Products named: FANAPT, REXULTI, VRAYLAR, WAKIX, Dyanavel XR, INGREZZA, Jornay PM, COBENFY.
Industry payments across IA — which companies pay providers there.
